




Belgian Cancer Registry

CANCER FACT SHEET 2023

CORPUS UTERI CANCER

ICD-10 C54



CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ($=200 \times 1.05$) and 255/100,000 over 5 years ($=200 \times (1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2023, obtained from the Statbel website.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.



1. CANCER INCIDENCE	5
1.1. Corpus uteri cancer incidence: by region	5
1.1.1. Corpus uteri cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2023.....	5
1.2. Corpus uteri cancer incidence: by tumour stage	6
1.2.1. Corpus uteri cancer incidence by clinical stage (cStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023.....	6
1.2.2. Corpus uteri cancer incidence by pathological stage (pStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023	6
1.2.3. Corpus uteri cancer incidence by stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023.....	7
1.2.4. Corpus uteri cancer incidence by tumour type and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023.....	8
1.2.5. Corpus uteri cancer incidence by tumour type, stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023.....	9
2. CANCER INCIDENCE TRENDS	10
2.1. Corpus uteri cancer incidence trends: by region.....	10
2.1.1. Corpus uteri cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023	10
2.2. Corpus uteri cancer incidence trends: by tumour stage.....	11
2.2.1. Corpus uteri cancer incidence trends by stage: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards	11
2.3. Corpus uteri cancer incidence trends: by tumour type.....	12
2.3.1. Corpus uteri cancer incidence trends by type: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023	12
2.4. Corpus uteri cancer incidence trends: by age group.....	13
2.4.1. Corpus uteri cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023.....	13
3. CANCER PREVALENCE	14
3.1. Corpus uteri cancer prevalence: by region.....	14
3.1.1. Corpus uteri cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2023.....	14
4. CANCER SURVIVAL.....	15
4.1. Corpus uteri cancer survival: by region	15
4.1.1. Corpus uteri cancer survival by region and age group: number at risk and net survival probabilities, 2019-2023	15
4.2. Corpus uteri cancer survival: by tumour type and tumour stage	17
4.2.1. Corpus uteri cancer survival by type and clinical stage (cStage): number at risk and net survival probabilities, 2019-2023	17
4.2.2. Corpus uteri cancer survival by type and pathological stage (pStage): number at risk and net survival probabilities, 2019-2023	19

4.2.3. Corpus uteri cancer survival by type and stage: number at risk and net survival probabilities, 2019-2023	21
5. CANCER SURVIVAL TRENDS.....	23
5.1. Corpus uteri cancer survival trends: by tumour stage.....	23
5.1.1. Corpus uteri cancer survival trends by stage: number at risk and net survival probabilities, 2004-2023	23
5.2. Corpus uteri cancer survival trends: by tumour type and tumour stage	25
5.2.1. Corpus uteri cancer survival trends by type and stage: number at risk and net survival probabilities, 2004-2023	25
6. CANCER MORTALITY	29
6.1. Corpus uteri cancer mortality: by region	29
6.1.1. Corpus uteri cancer mortality* by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021	29
7. CANCER MORTALITY TRENDS.....	30
7.1. Corpus uteri cancer mortality trends: by region.....	30
7.1.1. Corpus uteri cancer mortality* trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021	30

1. CANCER INCIDENCE



1.1. Corpus uteri cancer incidence: by region

1.1.1. *Corpus uteri cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2023*

N [CR]																						ESR2013 (95%CI)	
Region	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages		
Females																							
Belgium	0	0	0	0	0	1	1	7	17	33	64	128	192	207	219	228	159	119	32	3	1,410	22.1	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[1.8]	[4.4]	[9.0]	[16.5]	[32.2]	[50.3]	[61.1]	[73.7]	[92.8]	[91.3]	[88.9]	[45.2]	[14.4]	[23.8]	(21.0; 23.3)	
Brussels	0	0	0	0	0	0	0	0	3	5	9	15	15	9	16	12	6	12	3	0	105	20.6	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[6.6]	[12.2]	[23.5]	[44.0]	[49.6]	[36.0]	[74.6]	[66.7]	[46.7]	[122.4]	[52.9]	[0.0]	[16.6]	(16.6; 24.6)	
Flanders	0	0	0	0	0	0	1	4	9	14	31	70	111	125	114	151	108	78	19	3	838	21.6	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.9]	[4.1]	[6.7]	[13.8]	[29.6]	[48.6]	[61.8]	[64.9]	[100.5]	[98.7]	[91.4]	[43.2]	[24.5]	[24.5]	(20.1; 23.1)	
Wallonia	0	0	0	0	0	1	0	3	5	14	24	43	66	73	89	65	45	29	10	0	467	23.2	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[2.5]	[4.2]	[11.8]	[19.1]	[34.0]	[53.6]	[65.5]	[89.0]	[83.9]	[86.7]	[75.0]	[47.2]	[0.0]	[24.8]	(21.1; 25.3)	

1.2. Corpus uteri cancer incidence: by tumour stage

1.2.1. *Corpus uteri cancer incidence by clinical stage (cStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023*

cStage	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages	
I	77 [2.6]	499 [35.3]	323 [50.0]	899 [15.1]	14.2 (13.3; 15.1)
II	2 [0.1]	28 [2.0]	32 [5.0]	62 [1.0]	0.9 (0.7; 1.2)
III	5 [0.2]	63 [4.5]	54 [8.4]	122 [2.1]	1.9 (1.5; 2.2)
IV	9 [0.3]	52 [3.7]	66 [10.2]	127 [2.1]	1.9 (1.6; 2.3)
X/NA	30 [1.0]	104 [7.4]	66 [10.2]	200 [3.4]	3.2 (2.7; 3.6)

1.2.2. *Corpus uteri cancer incidence by pathological stage (pStage) and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023*

pStage	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages	
I	84 [2.9]	539 [38.1]	308 [47.7]	931 [15.7]	14.8 (13.8; 15.7)
II	8 [0.3]	30 [2.1]	39 [6.0]	77 [1.3]	1.2 (0.9; 1.5)
III	10 [0.3]	92 [6.5]	59 [9.1]	161 [2.7]	2.5 (2.1; 2.9)
IV	5 [0.2]	30 [2.1]	14 [2.2]	49 [0.8]	0.8 (0.6; 1.0)
X/NA	16 [0.5]	55 [3.9]	121 [18.7]	192 [3.2]	2.8 (2.4; 3.2)

1.2.3. Corpus uteri cancer incidence by stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

Stage	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages	
I	85 [2.9]	543 [38.4]	326 [50.5]	954 [16.1]	15.1 (14.1; 16.1)
II	7 [0.2]	32 [2.3]	44 [6.8]	83 [1.4]	1.3 (1.0; 1.6)
III	11 [0.4]	95 [6.7]	72 [11.2]	178 [3.0]	2.8 (2.3; 3.2)
IV	10 [0.3]	63 [4.5]	71 [11.0]	144 [2.4]	2.2 (1.9; 2.6)
X/NA	10 [0.3]	13 [0.9]	28 [4.3]	51 [0.9]	0.8 (0.6; 1.0)

1.2.4. Corpus uteri cancer incidence by tumour type and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

type	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages	
Endometrioid carcinoma	92 [3.1]	584 [41.3]	360 [55.8]	1,036 [17.5]	16.3 (15.3; 17.3)
Serous carcinoma	2 [0.1]	61 [4.3]	84 [13.0]	147 [2.5]	2.3 (1.9; 2.6)
Other and unspecified	29 [1.0]	101 [7.1]	97 [15.0]	227 [3.8]	3.5 (3.1; 4.0)

1.2.5. Corpus uteri cancer incidence by tumour type, stage and age group: number of new diagnoses, crude and age-standardised incidence rates, 2023

type	Stage	N[CR]				ESR2013 (95%CI)
		15-54	55-74	75+	All ages	
Endometrioid carcinoma	I	73 [2.5]	465 [32.9]	251 [38.9]	789 [13.3]	12.5 (11.6; 13.4)
	II	4 [0.1]	20 [1.4]	28 [4.3]	52 [0.9]	0.8 (0.6; 1.0)
	III	8 [0.3]	61 [4.3]	44 [6.8]	113 [1.9]	1.7 (1.4; 2.1)
	IV	3 [0.1]	29 [2.1]	22 [3.4]	54 [0.9]	0.8 (0.6; 1.1)
	X/NA	4 [0.1]	8 [0.6]	15 [2.3]	27 [0.5]	0.4 (0.3; 0.6)
Serous carcinoma	I	1 [0.0]	28 [2.0]	40 [6.2]	69 [1.2]	1.1 (0.8; 1.3)
	II	1 [0.0]	5 [0.4]	7 [1.1]	13 [0.2]	0.2 (0.1; 0.3)
	III	0 [0.0]	14 [1.0]	12 [1.9]	26 [0.4]	0.4 (0.3; 0.6)
	IV	0 [0.0]	12 [0.8]	22 [3.4]	34 [0.6]	0.5 (0.3; 0.7)
	X/NA	0 [0.0]	2 [0.1]	3 [0.5]	5 [0.1]	0.1 (0.0; 0.1)
Other and unspecified	I	11 [0.4]	50 [3.5]	35 [5.4]	96 [1.6]	1.5 (1.2; 1.8)
	II	2 [0.1]	7 [0.5]	9 [1.4]	18 [0.3]	0.3 (0.1; 0.4)
	III	3 [0.1]	20 [1.4]	16 [2.5]	39 [0.7]	0.6 (0.4; 0.8)
	IV	7 [0.2]	22 [1.6]	27 [4.2]	56 [0.9]	0.9 (0.6; 1.1)
	X/NA	6 [0.2]	3 [0.2]	10 [1.5]	19 [0.3]	0.3 (0.2; 0.4)

2. CANCER INCIDENCE TRENDS



2.1. Corpus uteri cancer incidence trends: by region

2.1.1. Corpus uteri cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	N	1,432	1,382	1,348	1,393	1,466	1,462	1,419	1,430	1,451	1,391	1,464	1,457	1,445	1,400	1,441	1,347	1,308	1,422	1,382	1,410		
	CR	27.0	25.9	25.1	25.8	26.9	26.7	25.7	25.6	25.8	24.6	25.8	25.5	25.2	24.3	24.9	23.2	22.4	24.3	23.5	23.8		
	ESR2013	28.1	26.9	26.1	26.6	27.5	27.2	26.0	26.0	26.1	24.4	25.5	25.3	25.0	23.7	24.1	22.3	21.3	22.9	22.2	22.1	-1.3 (-1.5; -1.0)	2004-2023
Brussels	N	111	105	102	103	116	122	113	100	80	125	104	108	119	111	123	97	100	133	104	105		
	CR	21.4	20.1	19.3	19.3	21.4	22.1	20.1	17.3	13.7	21.1	17.4	17.9	19.6	18.2	20.1	15.7	16.1	21.4	16.7	16.6		
	ESR2013	23.8	22.6	21.9	22.4	24.4	25.8	23.9	20.5	16.9	25.8	21.0	21.9	24.7	22.7	25.2	19.0	19.8	26.8	21.4	20.6	-0.3 (-1.3; 0.6)	2004-2023
Flanders	N	863	830	838	860	911	894	830	859	919	855	883	887	869	837	831	833	798	855	858	838		
	CR	28.3	27.1	27.2	27.7	29.2	28.4	26.2	26.9	28.6	26.5	27.2	27.2	26.5	25.4	25.1	25.0	23.8	25.5	25.4	24.5		
	ESR2013	29.0	27.4	27.6	27.9	29.0	28.2	25.7	26.3	27.8	25.1	25.8	25.9	25.0	23.8	23.0	23.0	21.7	22.8	22.9	21.6	-1.5 (-1.8; -1.2)	2004-2023
Wallonia	N	458	447	408	430	439	446	476	471	452	411	477	462	457	452	487	417	410	434	420	467		
	CR	26.3	25.6	23.2	24.3	24.7	25.0	26.5	26.0	24.8	22.5	26.0	25.1	24.8	24.4	26.3	22.4	22.0	23.3	22.5	24.8		
	ESR2013	27.7	27.0	24.6	25.2	25.5	25.5	26.9	26.7	25.3	22.8	25.8	24.9	24.8	23.6	25.5	21.7	20.9	22.1	20.9	23.2	-1.1 (-1.5; -0.7)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Corpus uteri cancer incidence trends: by tumour stage

2.2.1. Corpus uteri cancer incidence trends by stage: number of new diagnoses, crude and age-standardised incidence rates, 2019-2023, including average annual percentage change from 2004 onwards

Stage		2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
I	N	893	885	977	936	954		
	CR	15.4	15.2	16.7	15.9	16.1		
	ESR2013	15.0	14.6	16.0	15.1	15.1	0.6 (0.3; 1.0) 4.0 (3.1; 4.9) -1.7 (-2.3; -1.2)	2004-2023 2004-2012 2013-2023
II	N	82	64	77	83	83		
	CR	1.4	1.1	1.3	1.4	1.4		
	ESR2013	1.3	1.0	1.2	1.3	1.3	-2.3 (-3.2; -1.3)	2004-2023
III	N	173	162	171	174	178		
	CR	3.0	2.8	2.9	3.0	3.0		
	ESR2013	2.8	2.7	2.7	2.8	2.8	0.6 (-0.2; 1.3)	2004-2023
IV	N	115	123	128	134	144		
	CR	2.0	2.1	2.2	2.3	2.4		
	ESR2013	1.9	2.0	2.0	2.2	2.2	3.8 (2.8; 4.7)	2004-2023
X/NA	N	84	74	69	55	51		
	CR	1.4	1.3	1.2	0.9	0.9		
	ESR2013	1.3	1.1	1.0	0.8	0.8	-12.2 (-13.1; -11.3)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Corpus uteri cancer incidence trends: by tumour type

2.3.1. Corpus uteri cancer incidence trends by type: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

type		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Endometrioid carcinoma	N	885	861	868	905	982	1,033	943	1,002	1,041	985	1,041	1,043	1,023	1,013	1,026	968	958	1,033	990	1,036		
	CR	16.7	16.1	16.2	16.7	18.0	18.8	17.1	18.0	18.5	17.4	18.3	18.3	17.9	17.6	17.8	16.7	16.4	17.7	16.9	17.5		
	ESR2013	17.5	16.9	16.9	17.4	18.5	19.2	17.4	18.3	18.8	17.4	18.2	18.3	17.9	17.1	17.2	16.1	15.7	16.7	15.9	16.3	-0.4 (-0.8; -0.1)	2004-2023
																						1.2 (0.1; 2.2)	2004-2011
																						-0.9 (-2.5; 0.7)	2012-2015
																						-1.5 (-2.4; -0.6)	2016-2023
Serous carcinoma	N	47	52	53	74	78	98	83	91	93	96	114	110	128	119	147	117	123	145	147	147		
	CR	0.9	1.0	1.0	1.4	1.4	1.8	1.5	1.6	1.7	1.7	2.0	1.9	2.2	2.1	2.5	2.0	2.1	2.5	2.5	2.5		
	ESR2013	0.9	1.0	1.0	1.4	1.4	1.8	1.5	1.6	1.7	1.7	2.0	1.9	2.2	2.0	2.4	1.9	2.0	2.3	2.4	2.3	5.4 (4.5; 6.4)	2004-2023
																						13.3 (8.7; 18.0)	2004-2009
																						2.6 (-1.6; 6.9)	2010-2013
																						2.8 (1.1; 4.6)	2014-2023
Other and unspecified	N	500	469	427	414	406	331	393	337	317	310	309	304	294	268	268	262	227	244	245	227		
	CR	9.4	8.8	8.0	7.7	7.5	6.0	7.1	6.0	5.6	5.5	5.4	5.3	5.1	4.7	4.6	4.5	3.9	4.2	4.2	3.8		
	ESR2013	9.8	9.0	8.2	7.8	7.5	6.1	7.2	6.0	5.6	5.3	5.3	5.1	5.0	4.5	4.5	4.2	3.7	3.9	3.9	3.5	-5.1 (-5.5; -4.7)	2004-2023
																						-6.5 (-7.7; -5.3)	2004-2011
																						-4.3 (-5.0; -3.6)	2012-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4. Corpus uteri cancer incidence trends: by age group

2.4.1. Corpus uteri cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2023

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, %	(95%CI)	Period
15-54 N	161	154	158	160	162	156	148	140	122	141	151	157	147	128	127	120	105	120	130	123			
CR	5.7	5.5	5.6	5.6	5.7	5.4	5.1	4.8	4.2	4.8	5.2	5.4	5.1	4.4	4.4	4.2	3.6	4.2	4.5	4.2			
ESR2013	6.0	5.7	5.7	5.7	5.7	5.5	5.1	4.8	4.2	4.8	5.1	5.4	5.0	4.4	4.4	4.2	3.7	4.2	4.6	4.3	-1.9	(-2.5; -1.2)	2004-2023
55-74 N	854	804	813	812	820	836	785	806	856	744	772	819	801	775	825	744	720	772	735	746			
CR	78.0	72.8	73.2	72.7	72.8	73.3	67.9	68.6	71.7	61.4	62.8	65.5	62.8	59.4	62.0	54.9	52.3	55.4	52.4	52.7			
ESR2013	78.0	73.1	73.7	73.3	73.6	74.1	69.2	69.9	73.1	62.7	64.3	66.9	64.7	60.7	62.9	55.6	52.8	55.7	52.8	52.9	-2.1	(-2.4; -1.7)	2004-2023
																					-1.4	(-2.1; -0.7)	2004-2014
																					-2.8	(-3.5; -2.0)	2015-2023
75+ N	417	424	377	421	484	470	486	484	473	506	541	481	497	497	489	483	483	530	517	541			
CR	80.2	79.8	69.2	75.5	85.0	81.3	82.8	81.6	78.8	83.7	88.7	77.9	80.6	81.1	80.0	78.6	77.8	85.6	81.6	83.8			
ESR2013	78.8	78.9	68.7	75.2	84.6	80.9	82.6	82.2	78.8	83.6	89.6	78.8	83.3	82.7	81.7	81.3	81.2	87.3	84.8	85.7	0.5	(0.2; 0.9)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3. CANCER PREVALENCE



3.1. Corpus uteri cancer prevalence: by region

3.1.1. *Corpus uteri cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2023*

Region		Females				
		1-year	5-year	10-year	15-year	20-year
Belgium	N	1,325	5,533	9,984	13,479	16,191
	CR	22.2	92.7	167.3	226	271
	ESR2013	20.5	85.5	153.0	204.7	243.7
Brussels	N	98	428	756	978	1,141
	CR	15.4	67.1	118.6	153.4	179.0
	ESR2013	19.1	84.1	148.8	191.7	223.3
Flanders	N	789	3,390	6,117	8,350	10,081
	CR	22.9	98.4	177.6	242.4	292.7
	ESR2013	20.1	86.6	154.4	208.7	249.4
Wallonia	N	438	1,715	3,111	4,151	4,969
	CR	23.2	91.0	165.1	220.2	263.6
	ESR2013	21.5	83.4	150.3	199.0	236.6

4. CANCER SURVIVAL



4.1. Corpus uteri cancer survival: by region

4.1.1. *Corpus uteri cancer survival by region and age group: number at risk and net survival probabilities, 2019-2023*

Net Survival Probability, 2019-2023					
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
Females					
Belgium	All ages	14,015	91.5% (90.9%; 92.0%)	83.9% (83.1%; 84.7%)	81.1% (80.1%; 82.2%)
	15-54	1,133	96.2% (95.1%; 97.3%)	90.9% (89.2%; 92.7%)	88.2% (86.2%; 90.3%)
	55-74	7,684	94.4% (93.9%; 95.0%)	87.6% (86.8%; 88.5%)	84.6% (83.6%; 85.7%)
	75+	5,038	85.7% (84.5%; 86.9%)	76.5% (74.7%; 78.2%)	74.0% (71.7%; 76.4%)
Brussels	All ages	1,093	90.4% (88.4%; 92.5%)	80.8% (77.9%; 83.9%)	79.2% (75.6%; 83.0%)
	15-54	151	95.5% (92.2%; 98.9%)	89.7% (84.8%; 94.8%)	86.4% (80.6%; 92.6%)
	55-74	558	93.3% (91.1%; 95.5%)	84.1% (80.8%; 87.6%)	80.5% (76.6%; 84.6%)
	75+	371	84.1% (79.6%; 88.7%)	72.1% (65.8%; 79.1%)	74.1% (65.9%; 83.2%)
Flanders	All ages	8,454	91.7% (91.0%; 92.4%)	85.2% (84.2%; 86.2%)	83.3% (82.0%; 84.6%)
	15-54	614	95.8% (94.2%; 97.4%)	90.4% (88.0%; 92.9%)	87.7% (84.9%; 90.6%)
	55-74	4,572	94.9% (94.2%; 95.6%)	88.8% (87.7%; 89.9%)	86.8% (85.5%; 88.1%)
	75+	3,167	86.1% (84.6%; 87.6%)	78.7% (76.5%; 80.9%)	77.0% (74.1%; 80.0%)
Wallonia	All ages	4,468	91.3% (90.4%; 92.3%)	82.2% (80.8%; 83.7%)	77.6% (75.8%; 79.5%)
	15-54	368	97.2% (95.4%; 98.9%)	92.3% (89.5%; 95.2%)	89.8% (86.4%; 93.3%)

Net Survival Probability, 2019-2023					
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	55-74	2,554	93.9% (92.9%; 94.9%)	86.3% (84.8%; 87.8%)	81.6% (79.8%; 83.5%)
	75+	1,500	85.3% (83.1%; 87.4%)	72.9% (69.8%; 76.2%)	67.7% (63.5%; 72.2%)

4.2. Corpus uteri cancer survival: by tumour type and tumour stage

4.2.1. Corpus uteri cancer survival by type and clinical stage (cStage): number at risk and net survival probabilities, 2019-2023

type	cStage	Net Survival Probability, 2019-2023					
		N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)
Corpus uteri	All	14,015	91.5% (90.9%; 92.0%)	86.8% (86.1%; 87.5%)	83.9% (83.1%; 84.7%)	82.4% (81.5%; 83.3%)	81.1% (80.1%; 82.2%)
	I	6,541	98.8% (98.3%; 99.3%)	97.3% (96.6%; 98.0%)	95.7% (94.7%; 96.6%)	94.6% (93.5%; 95.8%)	93.9% (92.5%; 95.4%)
	II	438	91.6% (88.4%; 94.8%)	83.4% (79.1%; 88.0%)	79.7% (74.7%; 85.0%)	76.3% (70.7%; 82.4%)	73.0% (66.5%; 80.2%)
	III	945	80.9% (78.2%; 83.7%)	69.1% (65.9%; 72.5%)	60.1% (56.5%; 63.9%)	55.8% (51.9%; 59.9%)	54.6% (50.4%; 59.2%)
	IV	956	46.9% (43.7%; 50.2%)	32.0% (29.0%; 35.2%)	24.3% (21.5%; 27.5%)	21.5% (18.7%; 24.7%)	18.5% (15.6%; 21.8%)
	X/NA	5,143	92.3% (91.4%; 93.2%)	87.1% (86.0%; 88.3%)	84.6% (83.3%; 85.9%)	83.3% (81.9%; 84.8%)	82.0% (80.4%; 83.6%)
Endometrioid carcinoma	All	10,103	96.5% (96.0%; 97.0%)	94.7% (94.1%; 95.4%)	93.4% (92.6%; 94.2%)	92.5% (91.6%; 93.4%)	91.8% (90.7%; 92.9%)
	I	5,301	100.1% (99.7%; 100.5%)	100.1% (99.4%; 100.7%)	99.7% (98.8%; 100.6%)	99.5% (98.3%; 100.6%)	98.8% (97.3%; 100.3%)
	II	282	95.5% (92.2%; 98.9%)	88.8% (83.9%; 93.9%)	86.6% (80.9%; 92.7%)	83.2% (76.5%; 90.4%)	81.5% (74.0%; 89.8%)
	III	543	86.6% (83.5%; 89.9%)	79.7% (75.7%; 83.8%)	73.3% (68.8%; 78.1%)	68.5% (63.4%; 73.9%)	69.0% (63.4%; 75.2%)
	IV	367	55.5% (50.5%; 61.0%)	42.7% (37.7%; 48.4%)	34.6% (29.7%; 40.5%)	30.9% (25.9%; 36.8%)	29.6% (24.5%; 35.8%)
	X/NA	3,610	97.0% (96.2%; 97.8%)	94.9% (93.8%; 96.0%)	93.6% (92.4%; 94.9%)	92.8% (91.3%; 94.3%)	92.0% (90.3%; 93.8%)
Serous carcinoma	All	1,295	81.6% (79.3%; 83.9%)	66.2% (63.4%; 69.1%)	57.2% (54.1%; 60.4%)	52.5% (49.2%; 55.9%)	48.1% (44.6%; 51.8%)
	I	445	97.6% (95.3%; 99.8%)	86.1% (82.1%; 90.3%)	76.8% (71.8%; 82.2%)	71.4% (65.7%; 77.7%)	69.7% (63.2%; 76.8%)
	II	50	98.8% (93.3%; 104.6%)	83.5% (72.1%; 96.8%)	65.5% (51.6%; 83.0%)	59.0% (44.5%; 78.4%)	46.8% (31.3%; 70.2%)
	III	168	77.8% (71.4%; 84.9%)	57.9% (50.3%; 66.6%)	45.5% (37.8%; 54.9%)	41.2% (33.2%; 51.1%)	33.4% (25.0%; 44.7%)
	IV	227	49.2% (42.9%; 56.3%)	30.7% (25.1%; 37.7%)	22.6% (17.3%; 29.6%)	19.8% (14.5%; 26.9%)	12.9% (8.2%; 20.2%)
	X/NA	405	81.7% (77.6%; 85.9%)	65.6% (60.6%; 71.0%)	58.6% (53.4%; 64.3%)	53.7% (48.4%; 59.7%)	50.1% (44.6%; 56.4%)
Other and unspecified	All	2,630	77.0% (75.3%; 78.8%)	66.5% (64.6%; 68.6%)	60.6% (58.5%; 62.9%)	58.1% (55.9%; 60.5%)	56.4% (54.0%; 59.0%)
	I	796	91.0% (88.7%; 93.4%)	85.1% (82.1%; 88.2%)	79.4% (75.8%; 83.1%)	74.9% (70.8%; 79.3%)	74.5% (69.9%; 79.4%)

type	Net Survival Probability, 2019-2023						
	cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)
	II	106	77.8% (69.5%; 87.2%)	69.0% (59.3%; 80.4%)	68.1% (57.5%; 80.7%)	66.2% (54.6%; 80.2%)	63.5% (50.2%; 80.3%)
	III	234	69.8% (63.9%; 76.3%)	52.7% (46.1%; 60.1%)	40.1% (33.5%; 47.9%)	36.8% (30.3%; 44.9%)	35.9% (29.1%; 44.2%)
	IV	362	36.7% (32.0%; 42.2%)	21.7% (17.7%; 26.7%)	14.7% (11.2%; 19.3%)	12.9% (9.5%; 17.6%)	10.5% (7.2%; 15.4%)
	X/NA	1,136	81.3% (78.9%; 83.8%)	70.3% (67.4%; 73.4%)	65.3% (62.2%; 68.6%)	63.8% (60.4%; 67.3%)	61.5% (57.9%; 65.3%)

4.2.2. Corpus uteri cancer survival by type and pathological stage (pStage): number at risk and net survival probabilities, 2019-2023

type	pStage	Net Survival Probability, 2019-2023					
		N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)
Corpus uteri	All	14,015	91.5% (90.9%; 92.0%)	86.8% (86.1%; 87.5%)	83.9% (83.1%; 84.7%)	82.4% (81.5%; 83.3%)	81.1% (80.1%; 82.2%)
	I	9,216	100.0% (99.7%; 100.3%)	99.2% (98.7%; 99.8%)	98.4% (97.7%; 99.0%)	98.0% (97.2%; 98.9%)	97.6% (96.6%; 98.7%)
	II	705	95.4% (93.4%; 97.5%)	89.0% (86.0%; 92.1%)	84.8% (81.2%; 88.6%)	81.4% (77.2%; 85.8%)	79.8% (75.1%; 84.9%)
	III	1,525	90.0% (88.3%; 91.7%)	79.3% (77.0%; 81.7%)	70.7% (68.0%; 73.5%)	66.8% (63.9%; 69.9%)	63.0% (59.7%; 66.5%)
	IV	518	65.4% (61.3%; 69.8%)	45.0% (40.7%; 49.7%)	36.4% (32.2%; 41.2%)	31.7% (27.5%; 36.6%)	26.8% (22.6%; 31.8%)
	X/NA	2,058	59.6% (57.4%; 62.0%)	46.5% (44.2%; 49.0%)	40.6% (38.1%; 43.2%)	37.0% (34.4%; 39.7%)	35.0% (32.3%; 38.0%)
Endometrioid carcinoma	All	10,103	96.5% (96.0%; 97.0%)	94.7% (94.1%; 95.4%)	93.4% (92.6%; 94.2%)	92.5% (91.6%; 93.4%)	91.8% (90.7%; 92.9%)
	I	7,512	100.9% (100.6%; 101.1%)	101.4% (100.9%; 101.8%)	101.4% (100.7%; 102.0%)	101.6% (100.8%; 102.5%)	101.5% (100.4%; 102.5%)
	II	471	98.3% (96.3%; 100.3%)	94.7% (91.6%; 97.9%)	92.2% (88.3%; 96.3%)	89.7% (85.0%; 94.7%)	89.7% (84.3%; 95.5%)
	III	912	93.4% (91.5%; 95.4%)	88.9% (86.3%; 91.5%)	83.4% (80.3%; 86.6%)	79.7% (76.1%; 83.4%)	76.1% (72.0%; 80.6%)
	IV	153	76.9% (70.2%; 84.3%)	66.1% (58.4%; 74.7%)	59.9% (51.7%; 69.3%)	54.6% (46.1%; 64.7%)	50.4% (41.4%; 61.4%)
	X/NA	1,055	70.3% (67.3%; 73.4%)	56.6% (53.3%; 60.2%)	50.6% (47.0%; 54.5%)	45.5% (41.8%; 49.6%)	43.6% (39.6%; 48.1%)
Serous carcinoma	All	1,295	81.6% (79.3%; 83.9%)	66.2% (63.4%; 69.1%)	57.2% (54.1%; 60.4%)	52.5% (49.2%; 55.9%)	48.1% (44.6%; 51.8%)
	I	521	98.6% (96.8%; 100.5%)	91.5% (88.3%; 94.9%)	84.9% (80.8%; 89.3%)	80.3% (75.5%; 85.4%)	78.5% (73.0%; 84.3%)
	II	84	96.3% (90.7%; 102.2%)	82.0% (72.4%; 92.7%)	70.8% (59.6%; 84.1%)	67.9% (55.9%; 82.6%)	61.8% (48.7%; 78.5%)
	III	270	92.1% (88.4%; 95.9%)	68.3% (62.5%; 74.7%)	53.9% (47.5%; 61.1%)	47.8% (41.2%; 55.5%)	41.7% (34.8%; 49.8%)
	IV	161	65.6% (58.4%; 73.7%)	41.3% (34.0%; 50.1%)	29.5% (22.9%; 38.0%)	21.5% (15.5%; 29.9%)	12.2% (7.4%; 20.2%)
	X/NA	259	41.4% (35.6%; 48.1%)	23.4% (18.4%; 29.8%)	18.0% (13.3%; 24.3%)	16.1% (11.5%; 22.4%)	12.5% (8.1%; 19.1%)
Other and unspecified	All	2,630	77.0% (75.3%; 78.8%)	66.5% (64.6%; 68.6%)	60.6% (58.5%; 62.9%)	58.1% (55.9%; 60.5%)	56.4% (54.0%; 59.0%)
	I	1,190	95.1% (93.6%; 96.7%)	89.0% (86.8%; 91.3%)	85.1% (82.5%; 87.8%)	82.9% (79.9%; 86.0%)	81.6% (78.3%; 85.1%)
	II	150	85.8% (79.7%; 92.3%)	75.0% (67.4%; 83.5%)	69.5% (61.1%; 79.1%)	62.9% (53.8%; 73.5%)	59.1% (49.3%; 70.8%)
	III	343	79.2% (74.8%; 84.0%)	62.6% (57.3%; 68.5%)	50.5% (44.8%; 56.9%)	47.7% (41.7%; 54.5%)	45.0% (38.7%; 52.4%)
	IV	205	56.3% (49.7%; 63.6%)	31.9% (25.9%; 39.2%)	24.1% (18.5%; 31.4%)	22.4% (16.8%; 29.9%)	20.4% (14.8%; 28.1%)

Net Survival Probability, 2019-2023							
type	pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)
	X/NA	744	50.9% (47.3%; 54.9%)	40.2% (36.5%; 44.3%)	34.2% (30.4%; 38.4%)	32.0% (28.1%; 36.4%)	30.4% (26.3%; 35.1%)

4.2.3. Corpus uteri cancer survival by type and stage: number at risk and net survival probabilities, 2019-2023

type	Stage	Net Survival Probability, 2019-2023					
		N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)
Corpus uteri	All	14,015	91.5% (90.9%; 92.0%)	86.8% (86.1%; 87.5%)	83.9% (83.1%; 84.7%)	82.4% (81.5%; 83.3%)	81.1% (80.1%; 82.2%)
	I	9,466	99.4% (99.0%; 99.7%)	98.3% (97.8%; 98.9%)	97.2% (96.4%; 97.9%)	96.7% (95.9%; 97.6%)	96.3% (95.2%; 97.3%)
	II	753	92.3% (90.0%; 94.6%)	85.3% (82.1%; 88.6%)	81.1% (77.4%; 84.9%)	77.8% (73.6%; 82.2%)	76.6% (72.0%; 81.6%)
	III	1,672	85.7% (83.8%; 87.6%)	74.2% (71.8%; 76.6%)	66.2% (63.5%; 68.9%)	61.9% (59.0%; 64.9%)	58.0% (54.8%; 61.4%)
	IV	1,178	51.5% (48.6%; 54.5%)	34.7% (32.0%; 37.7%)	26.9% (24.2%; 29.8%)	23.1% (20.5%; 26.1%)	19.6% (17.0%; 22.7%)
	X/NA	953	72.1% (69.0%; 75.3%)	60.1% (56.6%; 63.7%)	55.5% (51.9%; 59.5%)	51.8% (47.9%; 56.0%)	50.0% (45.9%; 54.5%)
Endometrioid carcinoma	All	10,103	96.5% (96.0%; 97.0%)	94.7% (94.1%; 95.4%)	93.4% (92.6%; 94.2%)	92.5% (91.6%; 93.4%)	91.8% (90.7%; 92.9%)
	I	7,690	100.4% (100.1%; 100.8%)	100.6% (100.1%; 101.1%)	100.4% (99.7%; 101.1%)	100.5% (99.6%; 101.4%)	100.3% (99.2%; 101.4%)
	II	498	96.2% (93.9%; 98.6%)	91.3% (87.9%; 94.8%)	88.3% (84.2%; 92.6%)	85.6% (80.8%; 90.7%)	85.7% (80.3%; 91.5%)
	III	990	90.0% (87.9%; 92.2%)	83.8% (81.1%; 86.7%)	78.7% (75.5%; 82.1%)	74.3% (70.7%; 78.1%)	70.6% (66.4%; 75.1%)
	IV	433	59.1% (54.5%; 64.1%)	46.5% (41.7%; 51.7%)	38.6% (33.8%; 44.0%)	34.2% (29.4%; 39.8%)	32.0% (27.1%; 37.9%)
	X/NA	492	81.3% (77.5%; 85.3%)	71.1% (66.5%; 76.0%)	67.0% (62.0%; 72.5%)	62.3% (56.8%; 68.3%)	60.0% (54.1%; 66.6%)
Serous carcinoma	All	1,295	81.6% (79.3%; 83.9%)	66.2% (63.4%; 69.1%)	57.2% (54.1%; 60.4%)	52.5% (49.2%; 55.9%)	48.1% (44.6%; 51.8%)
	I	535	97.9% (95.9%; 99.9%)	90.8% (87.6%; 94.2%)	83.5% (79.3%; 87.9%)	79.0% (74.3%; 84.2%)	77.4% (71.9%; 83.2%)
	II	88	95.5% (89.8%; 101.6%)	79.2% (69.5%; 90.2%)	68.4% (57.3%; 81.6%)	65.7% (53.8%; 80.1%)	59.8% (47.0%; 76.1%)
	III	295	85.0% (80.6%; 89.6%)	61.9% (56.1%; 68.2%)	48.9% (42.9%; 55.8%)	43.5% (37.3%; 50.7%)	37.6% (31.3%; 45.2%)
	IV	287	55.8% (50.2%; 62.1%)	35.0% (29.6%; 41.3%)	25.6% (20.6%; 31.9%)	20.3% (15.5%; 26.5%)	12.2% (8.1%; 18.4%)
	X/NA	90	41.9% (32.4%; 54.2%)	21.4% (13.8%; 33.0%)	18.6% (11.5%; 29.9%)	14.6% (8.4%; 25.4%)	12.2% (6.5%; 23.1%)
Other and unspecified	All	2,630	77.0% (75.3%; 78.8%)	66.5% (64.6%; 68.6%)	60.6% (58.5%; 62.9%)	58.1% (55.9%; 60.5%)	56.4% (54.0%; 59.0%)
	I	1,248	93.4% (91.7%; 95.1%)	87.6% (85.3%; 89.9%)	83.2% (80.5%; 86.0%)	81.1% (78.1%; 84.2%)	79.5% (76.1%; 83.1%)
	II	167	78.7% (72.2%; 85.9%)	70.5% (62.9%; 79.1%)	66.2% (57.9%; 75.6%)	60.7% (51.8%; 71.2%)	58.4% (48.7%; 69.9%)
	III	387	75.2% (70.8%; 79.9%)	59.1% (54.0%; 64.7%)	47.8% (42.4%; 53.8%)	44.7% (39.1%; 51.1%)	42.0% (36.1%; 48.8%)

type	Net Survival Probability, 2019-2023						
	Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)
	IV	459	41.4% (37.1%; 46.3%)	23.4% (19.7%; 27.9%)	16.5% (13.2%; 20.7%)	14.2% (11.0%; 18.4%)	12.1% (8.9%; 16.5%)
	X/NA	371	67.0% (62.1%; 72.4%)	54.8% (49.4%; 60.8%)	49.3% (43.7%; 55.6%)	47.0% (41.1%; 53.7%)	46.1% (40.0%; 53.3%)

5. CANCER SURVIVAL TRENDS



5.1. Corpus uteri cancer survival trends: by tumour stage

5.1.1. *Corpus uteri cancer survival trends by stage: number at risk and net survival probabilities, 2004-2023*

Period	Stage	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2008	All	6,994	92.3% (91.6%; 93.0%)	83.4% (82.3%; 84.5%)	79.0% (77.7%; 80.4%)
	I	3,649	99.0% (98.4%; 99.6%)	96.1% (94.9%; 97.2%)	93.7% (92.1%; 95.2%)
	II	469	96.0% (93.6%; 98.4%)	85.4% (81.2%; 89.7%)	79.2% (74.1%; 84.8%)
	III	688	84.9% (82.1%; 87.9%)	58.7% (54.7%; 62.9%)	49.3% (45.1%; 53.9%)
	IV	308	53.6% (48.2%; 59.7%)	27.3% (22.5%; 33.0%)	20.4% (16.0%; 25.9%)
	X/NA	1,885	87.4% (85.7%; 89.1%)	76.4% (74.1%; 78.7%)	70.9% (68.2%; 73.7%)
2009-2013	All	7,139	91.1% (90.3%; 91.8%)	82.9% (81.8%; 84.0%)	79.7% (78.4%; 81.1%)
	I	4,651	98.6% (98.0%; 99.2%)	95.7% (94.7%; 96.7%)	94.1% (92.7%; 95.5%)
	II	392	92.1% (88.9%; 95.4%)	80.9% (75.9%; 86.2%)	74.4% (68.3%; 81.1%)
	III	698	81.2% (78.1%; 84.4%)	57.3% (53.3%; 61.5%)	49.5% (45.3%; 54.0%)
	IV	401	52.4% (47.6%; 57.7%)	27.8% (23.5%; 32.9%)	21.7% (17.7%; 26.7%)
	X/NA	999	78.1% (75.4%; 81.0%)	64.0% (60.7%; 67.5%)	59.2% (55.4%; 63.3%)
2014-2018	All	7,164	91.9% (91.2%; 92.7%)	84.1% (83.0%; 85.2%)	81.0% (79.6%; 82.3%)
	I	4,831	99.5% (99.0%; 100.0%)	96.8% (95.8%; 97.8%)	95.5% (94.1%; 96.8%)
	II	365	92.3% (89.0%; 95.7%)	81.0% (75.9%; 86.4%)	75.7% (69.6%; 82.4%)
	III	814	85.5% (82.9%; 88.2%)	65.0% (61.4%; 68.9%)	56.0% (52.0%; 60.4%)

Period	Stage	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	IV	534	51.0% (46.8%; 55.6%)	26.0% (22.3%; 30.2%)	19.5% (16.1%; 23.5%)
	X/NA	626	76.2% (72.6%; 80.0%)	62.0% (57.6%; 66.7%)	56.4% (51.5%; 61.8%)
2019-2023	All	6,851	91.0% (90.2%; 91.8%)	83.8% (82.6%; 85.0%)	81.8% (80.1%; 83.5%)
	I	4,635	99.2% (98.7%; 99.8%)	97.6% (96.5%; 98.7%)	97.4% (95.5%; 99.3%)
	II	388	92.2% (89.0%; 95.6%)	81.3% (76.2%; 86.9%)	78.2% (71.1%; 86.0%)
	III	858	85.9% (83.3%; 88.5%)	67.8% (64.0%; 71.8%)	62.7% (57.6%; 68.1%)
	IV	644	51.8% (48.0%; 56.0%)	27.7% (24.0%; 31.9%)	19.0% (14.6%; 24.7%)
	X/NA	327	64.2% (58.8%; 70.1%)	42.8% (36.6%; 49.9%)	36.0% (28.7%; 45.1%)

5.2. Corpus uteri cancer survival trends: by tumour type and tumour stage

5.2.1. *Corpus uteri cancer survival trends by type and stage: number at risk and net survival probabilities, 2004-2023*

Period	type	Stage	Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2008	Endometrioid carcinoma	All	4,496	96.3% (95.6%; 97.0%)	90.5% (89.3%; 91.8%)	86.8% (85.3%; 88.4%)
		I	2,813	99.5% (98.9%; 100.2%)	97.6% (96.4%; 98.8%)	95.7% (94.0%; 97.4%)
		II	331	98.2% (95.9%; 100.5%)	91.3% (86.9%; 95.9%)	86.7% (80.9%; 93.0%)
		III	376	88.7% (85.2%; 92.4%)	68.6% (63.4%; 74.2%)	61.0% (55.2%; 67.4%)
		IV	137	61.2% (53.4%; 70.2%)	32.9% (25.6%; 42.3%)	25.5% (18.7%; 34.8%)
		X/NA	839	93.7% (91.7%; 95.8%)	85.8% (82.7%; 89.0%)	78.8% (74.7%; 83.1%)
	Serous carcinoma	All	304	87.1% (83.0%; 91.4%)	53.8% (48.0%; 60.4%)	44.2% (38.3%; 51.2%)
		I	89	96.0% (90.6%; 101.8%)	88.1% (79.1%; 98.0%)	79.9% (68.7%; 92.8%)
		II	20	N<50	N<50	N<50
		III	92	86.7% (79.4%; 94.7%)	40.2% (31.0%; 52.2%)	27.2% (18.9%; 39.0%)
		IV	39	N<50	N<50	N<50
		X/NA	64	86.7% (78.0%; 96.3%)	45.0% (33.6%; 60.3%)	37.5% (26.4%; 53.2%)
	Other and unspecified	All	2,199	84.8% (83.2%; 86.5%)	72.7% (70.6%; 74.9%)	67.7% (65.3%; 70.2%)
		I	747	97.4% (95.8%; 99.0%)	91.3% (88.4%; 94.3%)	87.8% (84.0%; 91.7%)
		II	118	91.1% (85.2%; 97.4%)	75.5% (66.7%; 85.6%)	66.8% (56.4%; 79.0%)
		III	220	77.8% (72.2%; 83.9%)	49.6% (42.9%; 57.3%)	38.7% (32.1%; 46.7%)
		IV	132	41.5% (33.7%; 51.0%)	21.4% (15.2%; 30.2%)	14.5% (9.2%; 22.6%)
		X/NA	985	81.8% (79.3%; 84.5%)	70.2% (67.0%; 73.6%)	66.1% (62.5%; 69.9%)
2009-2013	Endometrioid carcinoma	All	5,000	95.9% (95.2%; 96.6%)	91.0% (89.9%; 92.2%)	89.0% (87.5%; 90.4%)
		I	3,667	99.7% (99.2%; 100.2%)	98.0% (96.9%; 99.0%)	97.2% (95.8%; 98.7%)

Period	type	Stage	Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		II	281	97.6% (94.8%; 100.5%)	90.7% (85.4%; 96.3%)	85.3% (78.3%; 93.0%)
		III	412	84.2% (80.5%; 88.1%)	67.0% (62.1%; 72.4%)	60.2% (54.8%; 66.1%)
		IV	142	60.6% (52.8%; 69.5%)	39.8% (32.0%; 49.5%)	32.2% (24.7%; 42.1%)
		X/NA	498	86.9% (83.6%; 90.3%)	74.5% (70.0%; 79.3%)	70.0% (64.5%; 76.0%)
	Serous carcinoma	All	461	83.4% (79.7%; 87.2%)	56.4% (51.5%; 61.8%)	48.0% (42.8%; 53.9%)
		I	189	96.4% (92.8%; 100.1%)	81.5% (74.8%; 88.8%)	74.8% (66.7%; 83.8%)
		II	25	N<50	N<50	N<50
		III	107	80.4% (72.5%; 89.1%)	43.0% (33.7%; 54.7%)	28.6% (20.0%; 40.8%)
		IV	79	68.8% (58.9%; 80.4%)	26.6% (18.1%; 39.2%)	21.1% (13.4%; 33.2%)
		X/NA	61	66.0% (54.7%; 79.6%)	41.4% (30.1%; 57.0%)	38.6% (26.8%; 55.4%)
	Other and unspecified	All	1,683	78.8% (76.7%; 80.9%)	65.9% (63.4%; 68.6%)	61.0% (58.1%; 64.0%)
		I	797	94.0% (92.0%; 96.0%)	88.6% (85.6%; 91.7%)	84.4% (80.5%; 88.5%)
		II	86	75.7% (66.5%; 86.1%)	55.9% (45.1%; 69.2%)	49.3% (37.9%; 64.1%)
		III	179	74.7% (68.3%; 81.8%)	43.5% (36.3%; 52.1%)	37.4% (30.1%; 46.4%)
		IV	180	38.8% (32.1%; 46.8%)	19.0% (13.8%; 26.0%)	13.8% (9.2%; 20.6%)
		X/NA	441	69.7% (65.4%; 74.4%)	55.2% (50.2%; 60.7%)	49.7% (44.3%; 55.7%)
2014-2018	Endometrioid carcinoma	All	5,127	96.5% (95.8%; 97.2%)	93.1% (92.1%; 94.2%)	91.3% (89.8%; 92.7%)
		I	3,876	100.6% (100.1%; 101.0%)	99.9% (99.0%; 100.9%)	99.7% (98.3%; 101.1%)
		II	240	94.4% (90.8%; 98.2%)	87.0% (81.3%; 93.1%)	83.1% (75.9%; 90.9%)
		III	481	88.8% (85.7%; 92.0%)	77.2% (72.8%; 81.8%)	67.5% (62.2%; 73.2%)
		IV	192	56.4% (49.6%; 64.2%)	39.3% (32.5%; 47.4%)	35.8% (28.9%; 44.2%)
		X/NA	338	84.6% (80.3%; 89.1%)	72.6% (66.8%; 78.9%)	66.1% (59.3%; 73.7%)
	Serous carcinoma	All	617	82.6% (79.4%; 86.0%)	56.9% (52.7%; 61.5%)	47.6% (43.2%; 52.6%)
		I	261	97.9% (95.1%; 100.8%)	82.7% (77.0%; 88.8%)	76.3% (69.4%; 83.9%)

Period	type	Stage	Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		II	43	N<50	N<50	N<50
		III	133	88.4% (82.6%; 94.6%)	46.5% (38.3%; 56.4%)	35.6% (27.7%; 45.7%)
		IV	127	56.9% (48.7%; 66.5%)	24.7% (17.9%; 34.1%)	11.1% (6.5%; 19.0%)
		X/NA	53	42.3% (30.4%; 58.7%)	29.6% (18.8%; 46.8%)	19.0% (10.1%; 35.8%)
	Other and unspecified	All	1,430	79.6% (77.3%; 81.9%)	63.3% (60.5%; 66.2%)	58.4% (55.2%; 61.7%)
		I	699	94.2% (92.1%; 96.4%)	84.4% (81.0%; 87.9%)	79.5% (75.3%; 84.0%)
		II	82	83.6% (75.1%; 93.1%)	73.2% (62.1%; 86.3%)	65.4% (52.8%; 81.0%)
		III	200	75.8% (69.7%; 82.4%)	48.1% (41.0%; 56.4%)	42.2% (34.7%; 51.3%)
		IV	216	42.5% (36.3%; 49.8%)	15.0% (10.8%; 20.8%)	10.1% (6.6%; 15.4%)
		X/NA	235	71.6% (65.6%; 78.2%)	53.9% (47.0%; 61.9%)	50.7% (43.2%; 59.6%)
2019-2023	Endometrioid carcinoma	All	4,976	96.5% (95.9%; 97.2%)	93.7% (92.6%; 94.9%)	92.6% (90.7%; 94.6%)
		I	3,814	100.3% (99.8%; 100.8%)	100.8% (99.8%; 101.9%)	101.0% (99.0%; 103.0%)
		II	258	97.9% (95.0%; 100.8%)	89.7% (84.0%; 95.7%)	90.1% (82.3%; 98.6%)
		III	509	91.2% (88.2%; 94.2%)	80.6% (76.0%; 85.5%)	77.4% (70.7%; 84.9%)
		IV	241	61.3% (55.2%; 68.0%)	38.1% (31.7%; 45.8%)	26.7% (19.7%; 36.1%)
		X/NA	154	74.2% (66.8%; 82.3%)	54.6% (45.4%; 65.7%)	43.0% (31.6%; 58.4%)
	Serous carcinoma	All	678	80.6% (77.5%; 84.0%)	57.6% (53.3%; 62.3%)	49.7% (44.3%; 55.8%)
		I	274	97.8% (95.1%; 100.7%)	83.9% (77.8%; 90.5%)	80.1% (71.9%; 89.3%)
		II	45	N<50	N<50	N<50
		III	162	82.3% (76.0%; 89.0%)	51.9% (43.6%; 61.8%)	40.9% (31.5%; 53.2%)
		IV	160	55.0% (47.6%; 63.5%)	26.6% (20.0%; 35.6%)	15.2% (8.4%; 27.6%)
		X/NA	37	N<50	N<50	N<50
	Other and unspecified	All	1,200	73.9% (71.3%; 76.7%)	57.1% (53.9%; 60.6%)	54.3% (50.3%; 58.7%)
		I	549	92.3% (89.6%; 95.0%)	81.6% (77.3%; 86.1%)	80.8% (75.2%; 86.9%)

Period	type	Stage	Net Survival Probability			
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		II	85	74.0% (64.5%; 84.9%)	57.5% (45.8%; 72.1%)	47.7% (33.4%; 68.1%)
		III	187	74.6% (68.2%; 81.5%)	47.4% (39.7%; 56.5%)	42.8% (34.5%; 53.2%)
		IV	243	40.4% (34.6%; 47.3%)	17.9% (13.2%; 24.4%)	14.4% (8.8%; 23.4%)
		X/NA	136	59.1% (50.9%; 68.6%)	41.0% (32.1%; 52.3%)	37.4% (27.3%; 51.1%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

6. CANCER MORTALITY



6.1. Corpus uteri cancer mortality: by region

6.1.1. *Corpus uteri cancer mortality* by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021*

Region	N [CR]																					ESR2013 (95%CI)
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Belgium	0	0	0	0	0	0	0	0	1	0	5	8	13	26	38	55	46	40	22	7	261	4.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.0]	[1.3]	[2.0]	[3.5]	[8.0]	[12.8]	[25.8]	[24.9]	[29.6]	[33.2]	[36.4]	[4.5]	(3.5; 4.5)
Brussels	0	0	0	0	0	0	0	0	0	0	1	1	3	0	5	3	0	5	1	0	19	3.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.7]	[3.0]	[10.1]	[0.0]	[23.2]	[18.5]	[0.0]	[49.2]	[17.4]	[0.0]	[3.1]	(2.0; 5.5)
Flanders	0	0	0	0	0	0	0	0	1	0	2	4	7	19	23	37	31	25	16	7	172	4.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[0.9]	[1.7]	[3.2]	[9.8]	[13.2]	[27.8]	[26.7]	[29.4]	[39.9]	[62.3]	[5.1]	(3.6; 4.9)
Wallonia	0	0	0	0	0	0	0	0	0	0	2	3	3	7	10	15	15	10	5	0	70	3.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.6]	[2.4]	[2.5]	[6.4]	[9.9]	[23.5]	[27.2]	[25.0]	[24.5]	[0.0]	[3.8]	(2.6; 4.3)

7. CANCER MORTALITY TRENDS



7.1. Corpus uteri cancer mortality trends: by region

7.1.1. *Corpus uteri cancer mortality* trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	N	181	186	181	190	219	200	209	201	188	214	228	209	230	232	237	233	227	261	0.4 (-0.1; 0.9)	2004-2021
	CR	3.4	3.5	3.4	3.5	4.0	3.6	3.8	3.6	3.3	3.8	4.0	3.7	4.0	4.0	4.1	4.0	3.9	4.5		
	ESR2013	3.4	3.4	3.3	3.4	3.9	3.6	3.6	3.4	3.2	3.6	3.7	3.4	3.7	3.7	3.7	3.4	3.5	4.0		
Brussels	N	18	14	14	17	21	11	7	17	17	12	14	15	21	15	14	15	16	19	0.7 (-2.0; 3.4)	2004-2021
	CR	3.5	2.7	2.6	3.2	3.9	2.0	1.2	2.9	2.9	2.0	2.3	2.5	3.5	2.5	2.3	2.4	2.6	3.1		
	ESR2013	3.5	2.8	2.8	3.0	4.0	2.3	1.2	3.4	3.2	2.2	2.9	3.1	4.2	2.8	2.6	2.6	3.4	3.8		
Flanders	N	118	132	129	136	154	141	151	138	130	152	166	143	149	162	163	161	151	172	-0.3 (-0.8; 0.3)	2004-2021
	CR	3.9	4.3	4.2	4.4	4.9	4.5	4.8	4.3	4.0	4.7	5.1	4.4	4.5	4.9	4.9	4.8	4.5	5.1		
	ESR2013	3.9	4.3	4.1	4.2	4.7	4.3	4.5	4.0	3.8	4.3	4.4	3.8	3.9	4.2	4.2	3.9	3.8	4.3		
Wallonia	N	45	40	38	37	44	48	51	46	41	50	48	51	60	55	60	57	60	70	2.0 (1.0; 2.9)	2004-2021
	CR	2.6	2.3	2.2	2.1	2.5	2.7	2.8	2.5	2.3	2.7	2.6	2.8	3.3	3.0	3.2	3.1	3.2	3.8		
	ESR2013	2.6	2.1	2.2	2.1	2.4	2.7	2.7	2.5	2.1	2.7	2.4	2.7	3.2	2.8	2.9	2.7	3.0	3.5		

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Recommended reference: Cancer Fact Sheets 2023, Belgian Cancer Registry (BCR), 2025